Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

Ryota Tamura; Masato Fujioka; Yukina Morimoto; Kentaro Ohara; Kenzo Kosugi; Yumiko Oishi; Mizuto Sato; Ryo Ueda; Hirokazu Fujiwara; Tetsuro Hikichi; Shinobu Noji; Naoki Oishi; Kaoru Ogawa; Yutaka Kawakami; Takayuki Ohira; Kazunari Yoshida; Masahiro Toda

doi:10.1038/s41467-020-16007-z

Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

Ryota Tamura, Masato Fujioka, Yukina Morimoto, Kentaro Ohara, Kenzo Kosugi, Yumiko Oishi, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara, Tetsuro Hikichi, Shinobu Noji, Naoki Oishi, Kaoru Ogawa, Yutaka Kawakami, Takayuki Ohira, Kazunari Yoshida, Masahiro Toda

Research output: Contribution to journal › Comment/debate › peer-review

3 Citations (Scopus)

Abstract

The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.

Original language	English
Article number	2028
Journal	Nature communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-16007-z
Publication status	Published - 2020 Dec 1

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
General
Physics and Astronomy(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-020-16007-z

Cite this

Tamura, R., Fujioka, M., Morimoto, Y., Ohara, K., Kosugi, K., Oishi, Y., Sato, M., Ueda, R., Fujiwara, H., Hikichi, T., Noji, S., Oishi, N., Ogawa, K., Kawakami, Y., Ohira, T., Yoshida, K., & Toda, M. (2020). Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1). Nature communications, 11(1), [2028]. https://doi.org/10.1038/s41467-020-16007-z

Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1). / Tamura, Ryota; Fujioka, Masato; Morimoto, Yukina et al.
In: Nature communications, Vol. 11, No. 1, 2028, 01.12.2020.

Research output: Contribution to journal › Comment/debate › peer-review

Tamura, R, Fujioka, M, Morimoto, Y, Ohara, K, Kosugi, K, Oishi, Y, Sato, M, Ueda, R , Fujiwara, H, Hikichi, T, Noji, S, Oishi, N, Ogawa, K, Kawakami, Y, Ohira, T, Yoshida, K & Toda, M 2020, 'Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)', Nature communications, vol. 11, no. 1, 2028. https://doi.org/10.1038/s41467-020-16007-z

@article{3d6383a3f6854124bb46faa8c14df50a,

title = "Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)",

abstract = "The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.",

author = "Ryota Tamura and Masato Fujioka and Yukina Morimoto and Kentaro Ohara and Kenzo Kosugi and Yumiko Oishi and Mizuto Sato and Ryo Ueda and Hirokazu Fujiwara and Tetsuro Hikichi and Shinobu Noji and Naoki Oishi and Kaoru Ogawa and Yutaka Kawakami and Takayuki Ohira and Kazunari Yoshida and Masahiro Toda",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41467-020-16007-z",

language = "English",

volume = "11",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Author Correction

T2 - A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

AU - Tamura, Ryota

AU - Fujioka, Masato

AU - Morimoto, Yukina

AU - Ohara, Kentaro

AU - Kosugi, Kenzo

AU - Oishi, Yumiko

AU - Sato, Mizuto

AU - Ueda, Ryo

AU - Fujiwara, Hirokazu

AU - Hikichi, Tetsuro

AU - Noji, Shinobu

AU - Oishi, Naoki

AU - Ogawa, Kaoru

AU - Kawakami, Yutaka

AU - Ohira, Takayuki

AU - Yoshida, Kazunari

AU - Toda, Masahiro

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.

AB - The original version of this Article omitted from the author list the 10th author Tetsuro Hikichi, who is from OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012, Japan. This author has been added to the article. Consequently, the 5th sentence in the Authors Contributions has been modified to read “RT, MF, YM, KO, KK, YO, MS, NO, HF, TH, and SN collected the data”. Additionally, the following was added to the Competing Interests: TH is an employee of OncoTherapy Science, Inc. This has been corrected in both the PDF and HTML versions of the Article.

UR - http://www.scopus.com/inward/record.url?scp=85083758821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083758821&partnerID=8YFLogxK

U2 - 10.1038/s41467-020-16007-z

DO - 10.1038/s41467-020-16007-z

M3 - Comment/debate

C2 - 32317644

AN - SCOPUS:85083758821

SN - 2041-1723

VL - 11

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2028

ER -

Author Correction: A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (Nature Communications, (2019), 10, 1, (5758), 10.1038/s41467-019-13640-1)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this